Arcturus Therapeutics is trading 5.08% higher at $14.55, with no specific catalyst identified for the move.
- No company-specific announcement on September 28, 2026, was identified as the reason.
- The September 23 update reported interim Phase 2 ARCT-810 results and introduced the LUNAR 2.0 delivery platform.
- No source links that update to the gain; major indexes were slightly lower.